Spectrum reaches patent settlement with Fresenius

US biopharmaceutical company Spectrum Pharmaceuticals announced yesterday that it had reached a settlement with UK healthcare company Fresenius Kabi in a patent dispute centring on the drug Folotyn (pralatrexate).

The settlement is an outcome of the patent dispute between the two companies where Spectrum accused Fresenius of infringing three of its patents. It followed Fresenius’s Abbreviated New Drug Application with the US Food and Drug Administration to bring a generic version of the drug onto the market.

Details of the settlement are confidential.

Following this settlement, along with Spectrum’s other agreements with Teva Pharmaceuticals, Dr Reddy’s Laboratories and Sandoz, generic versions of the drug will not be allowed in the US until November 12, 2022.

Folotyn is a drug used for the treatment of T-cell lymphoma that has spread throughout the body.